Want to see SE:VITR full AI Analyst Report?
VITR Stock Chart & Stats
kr133.00
-kr3.40(-1.91%)
At close: 4:00 PM EST
kr133.00
-kr3.40(-1.91%)
Day’s Range― - ―
52-Week Rangekr84.60 - kr153.50
Previous CloseN/A
Volume81.91K
Average Volume (3M)92.36K
Market Cap
kr11.78B
Enterprise Valuekr13.24B
Total Cash (Recent Filing)kr886.00M
Total Debt (Recent Filing)kr1.58B
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Jul 16, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)-37.01
Shares Outstanding135,447,190
10 Day Avg. Volume105,869
30 Day Avg. Volume92,365
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio50.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.02
Revenue Forecast (FY)kr3.48B
Bulls Say, Bears Say
Bulls Say
Recurring ConsumablesVitrolife's core consumables and media business drives repeat purchases tied to IVF procedure volumes, creating predictable, recurring revenue. That recurring stream supports steady cash generation, higher customer retention, and resilience versus cyclical capital equipment sales over the medium term.
Strong Cash GenerationPositive and improving operating and free cash flow despite net losses provides durable financial flexibility. Reliable cash generation funds operations, product development, and distributor/support investments, reducing immediate financing risk and enabling strategic actions over coming quarters.
Low LeverageManageable leverage gives Vitrolife capacity to absorb earnings volatility and fund growth without heavy interest burdens. Low debt levels preserve credit optionality for capex or M&A and reduce refinancing vulnerability during periods of weaker profitability over the medium term.
Bears Say
Revenue WeaknessSustained revenue declines signal weakening end-market demand or share loss in IVF consumables and equipment. Lower top-line volumes pressure fixed-cost absorption, reduce scale economics, and constrain reinvestment capacity, making medium-term margin recovery and growth harder to achieve.
Volatile, Negative ProfitabilityLarge, persistent net losses and negative operating results erode equity and limit retained earnings for R&D and commercial expansion. Profitability volatility undermines planning, increases reliance on cash management, and raises execution risk for long-term strategic initiatives.
Eroding EquityMaterial equity decline reduces financial cushion against shocks and could force reliance on external capital if cash generation worsens. This raises the prospect of dilutive financing or constrained investment, limiting strategic flexibility over the next several quarters.
Vitrolife AB News
VITR FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was kr84.60 and its highest was kr153.50 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is kr11.78B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Jul 16, 2026 which is in 2 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Apr 23, 2026. The company reported kr0.74 earnings per share for the quarter, missing the consensus estimate of kr0.773 by -kr0.033.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB pays a Annually dividend of kr1.1 which represents an annual dividend yield of 0.8%. See more information on Vitrolife AB dividends here
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 0.9.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of kr0.74 in its last earnings report, missing expectations of kr0.773. Following the earnings report the stock price went up 12.265%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in SE:VITR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Options Prices
Currently, No data available
---